104383
Rongqin Huang Professor, Ph.D. supervisor, Outstanding Young Scientist funded by NSFC Targeted Drug Delivery
Huang Rongqin is a professor at the School of Pharmacy, Fudan University, a doctoral supervisor, and a winner of the National Outstanding Youth Science Fund. In 2003, she graduated from the School of Pharmacy, Fudan University. In 2008, she graduated from Fudan University with a Ph.D. in pharmaceutics. She was nominated for a national excellent doctoral dissertation. In 2010 and 2015, she went to the University of Munich and the University of California, Berkeley for research respectively. She has published more than 80 papers, including 57 corresponding/first author SCI papers, with SCI he-citations around 5,000 SCI. 22 invention patents have been applied for, 11 other invention patents have been authorized, and one PCT application has been filed. She has presided 13 national projects including the National Natural Science Foundation of China Excellent Youth Science Fund, International Cooperation Projects (2 projects), General Projects (3 projects), Youth Projects, Shanghai Natural Science Foundation, Shanghai Outstanding Academic Leaders, and Shanghai Pujiang Talent Program Or provincial and ministerial projects, and has won the second prize of the 2020 Higher Education Outstanding Scientific Research Achievement Award for Natural Science (the first author), the second prize of the 2019 Shanghai Pharmaceutical Science and Technology Award (the first author), the second prize of the 2020 Jiangsu Medical Science and Technology Award (the second author). She was selected into the World Economic Forum's 2019 Young Scientist List (21 selected globally). She is the chief editor of a monograph published by Springer Nature Press (2020, ISBN: 978-981-15-5158-1), serves as editorial board members of 6 Chinese and English journals including Journal of Gene Medicine and Asian Journal of Pharmaceutical Sciences, and reviewer of more than 60 journals including JACS and Adv Mater.
Research More >
Our researches focus on targeted drug delivery, combined cancer therapy and biomaterials.